Establishment Labs Holdings Inc.

ESTA Nasdaq SEC CIK 1688757
Follow Establishment Labs Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $72M +33.9% vs same quarter last year
Net income −$10.7M +3.9% vs same quarter last year
EPS, diluted −$0.35 +7.9% vs same quarter last year
Operating cash flow $7.7M +168.4% vs same quarter last year
Revenue by quarter
$44.5M
$41.4M
$51.3M
$53.8M
$64.6M
$59.9M
$67.5M
$72M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$100M$0$100M$200M$300MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$211.1M−$51.1M
FY24$166M−$84.6M
FY23$165.2M−$78.5M
FY22$161.7M−$75.2M
FY21$126.7M−$41.1M
FY20$84.7M−$38.1M
FY19$89.6M−$38.2M
FY18$61.2M−$21.1M
FY17$34.7M−$34.9M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−150%−100%−50%0%50%100%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2569.3%−18.5%−24.2%
FY2466%−30.1%−51%
FY2364.8%−39.4%−47.5%
FY2265.9%−24.5%−46.5%
FY2167.4%−19.8%−32.5%
FY2062%−33%−45%
FY1961.3%−34.5%−42.6%
FY1859%−39%−34.5%
FY1751%−57.6%−100.6%
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$56.9M
FY24−$64.6M
FY23−$96.4M
FY22−$55M
FY21−$30M
FY20−$14.6M
FY19−$36.3M
FY18−$35.6M
FY17−$32.9M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Establishment Labs
  • Healthcare median
−150%−100%−50%0%FY17FY19FY21FY23FY25
Show the numbers
YearEstablishment LabsHealthcare median
FY25−24.2%−30.6%
FY24−51%−47%
FY23−47.5%−58%
FY22−46.5%−80.4%
FY21−32.5%−71.9%
FY20−45%−62.2%
FY19−42.6%−46.3%
FY18−34.5%−49.6%
FY17−100.6%−45.9%
FY16-−36%